Category: Money tips Release Date: 2006-06-19
Source: Industrial Equity Research
G Southern drugs pull three consecutive limit-burst, the constant group, Tong Junge a strong impact on daily limit, Winbond pharmaceutical, G a substantial increase medical, pharmaceutical stocks to shine once again, pharmaceutical stocks worthy of eternal hot spot for the market, all all reflect the broad prospects for the pharmaceutical industry.
The surface from a policy perspective, according to the State Development and Reform Commission, "Pharmaceutical Industry" Eleventh Five-Year "development of guidance," "opinions" that will speed up the pharmaceutical distribution system, which will also bring real nature of good medicine. 2006 - 2010 Chinese medicine industry has ambitious development goals, the country's strong support for high-quality pharmaceutical stocks a huge development opportunities, medicine, new plates will lead to an upside opportunity for the outbreak of pharmaceutical stocks blowout, and this is expected to Pharmaceutical stocks have caused the strong side by side. From the medical section, we tap the great potential of the individual stocks to another G Ancient Han Dynasty (000.59 thousand quotes, information, advice, more) companies are all referred to as "Tsinghua Unisplendour Guhan Bio-Pharmaceutical Co., Ltd.", is the national Chinese medicine key top fifty industrial enterprises, one of the country's largest producers of western medicine preparations, should focus on strong.
G Gu Han (000.59 thousand): The company is committed to the research, development of traditional Chinese medicine recipe, prescription, medicine formulations and biological products, after a large investment in recent years, large adjustments, is currently being embarked on the "production generation, development of a generation, reserves generation "of healthy and benign operational orbit, the new economic growth point a gradual increase in capacity for sustained development and gradually enhanced, concentrated, West, biochemical medicine and health product in one of the unique product structure, leading enterprises in the national pharmaceutical industry has a relatively niche market competitive advantage. And according to the relevant international organizations estimated that the international medicine market growth will be about the existing annual sales of 30 billion U.S. dollars, based on an average annual growth rate of 10% increase in 10 years will reach 100 billion U.S. dollars sales volume, traditional Chinese medicine health industry will undoubtedly have broad market prospects. In addition, the company's leading product is based on ancient Chinese health essence of the bamboo slips unearthed in Changsha Mawangdui Medical Books "nutritious side" set of square, featuring authentic traditional Chinese medicine, the use of modern technology crafted with the treatment and health functions of the "quasi" Size Drugs is a combination of modern technology and traditional recipe of a classic.
It is noteworthy that such a high-quality company's first and the second largest shareholder equity ratio was 21.44%, respectively, and 20.58%, the ratio is very similar, that is owned 22% stake in the company can become the company's actual controller, the cost of a considerable low, broad space for development in the company before the two broke through the secondary market is very large stake in the possibility of contention.
The secondary market, the stock has maintained a strong momentum, stocks sexually active, and have been long-term care funding. As a leading Chinese medicine is currently only 3 per share price to climb, is QIFF the preferred target, a modest amount of amplification can also show appearance outside the capital were making inroads. With the G consecutive Southern drugs and other pharmaceutical stocks soared, and medical effects of significant profits plates very prominent, while the Unit is a small cloudy Thursday callback, the possibility of a great afternoon compensatory growth, cause for concern.
